1. |
- Alhashimi, N, et al.
(författare)
-
Chemokines are upregulated during orthodontic tooth movement
- 1999
-
Ingår i: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. - : Mary Ann Liebert Inc. - 1079-9907. ; 19:9, s. 1047-1052
-
Tidskriftsartikel (refereegranskat)
|
|
2. |
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
- Ruotsalainen, Tarja M., et al.
(författare)
-
Concomitant chemotherapy and IFN-alpha for small cell lung cancer : a randomized multicenter phase III study
- 1999
-
Ingår i: Journal of Interferon and Cytokine Research. - : Mary Ann Liebert Inc. - 1079-9907 .- 1557-7465. ; 19:3, s. 253-9
-
Tidskriftsartikel (refereegranskat)abstract
- Patients with any stage of small cell lung cancer were given low-dose interferon-alpha (IFN-alpha) from the first day of treatment as long as possible irrespective of changes in treatment dictated by disease progression. All patients received 6 cycles of the chemotherapy (CT): cisplatin 70 mg/m2 i.v. day 1 and etoposide 100 mg/m2 i.v. days 1, 2, 3 every 28 days. Seventy-eight patients were assigned to arm 1: CT alone, 75 patients to arm 2: CT + natural IFN-alpha (3 MU three times a week i.m.), and 66 patients to arm 3: CT + recombinant IFN alpha-2a (3 MU three times a week i.m.). There was no difference in median survival between the arms (10.2 months, 10.0 months, 10.1 months, respectively), p = 0.32. The 2-year survival rates were 15%, 3%, and 11%, respectively. Grade 3 and 4 leukopenia occurred more frequently in the IFN arms than in the CT alone arm and resulted in dose reductions. Antibodies occasionally developed to recombinant IFN. We conclude that IFN-alpha can be administered concomitantly with chemotherapy but is probably better kept for maintenance therapy so that optimal full doses of induction CT can be given.
|
|